Dr. Jos Buijs

Dr. Jos Buijs

Advisory Board Member

Dr. Buijs has over 3 decades’ experience in biotechnology with a focus on interaction analysis. He attained his PhD in Wageningen, the Netherlands, studying antibody interactions and continued as Post Doc at the University of Utah and research group leader at Uppsala University. In 2007, he was appointed as adjunct Professor in Biotechnology. He has been developing interactions analysis technology at Biacore (Cytiva) and was leading the design of the Biacore T200 and 8K systems. In 2013, he started as CTO at Ridgeview Instruments that provides LigandTracer instruments for interaction analysis on live cells. Currently, Jos is CEO and board member of Ridgeview Instruments AB and has an adjunct professor position at Uppsala University.

 

Hans Boumans

Hans Boumans

Board Member

Hans Boumans is director technology transfer at TNO and as such responsible for some 40 TNO spin-off companies. In addition, he is a member of the supervisory board of 4 of these companies. He is also a board member of the pension fund of TNO and a board member of a European organization regarding technology transfer.

Hans has a scientific background, holds a PhD in biochemistry and molecular biology.

 

Dr. Jan Groen

Dr. Jan Groen

Board Member

Dr. Jan Groen is the Chairman and Chief Executive Officer of Intravacc. He was previously the CEO of Novigenix (CH), a privately-owned immunotranscriptomic diagnostic company, and MDxHealth, a Public-listed genomic diagnostics company in the USA. His career spans many years in the global life science sector. He was the President and COO of Agendia (USA), co-founder of ViroClinics and DxOrange, and has held management and scientific positions at Focus Diagnostics (USA), the Erasmus Medical Center, the National Institute of Public Health, and Akzo-Nobel. Currently he is investment advisor at Oncode Institute, Chairman of the Board of Angle Plc. (UK), Board member of SPL Medical and Novigenix (CH). He has published over 125 papers in international scientific journals and holds a PhD in Medical Microbiology from Erasmus University Rotterdam.

 

Karel Kubias

Karel Kubias

Board Member

Karel has 20+ years leadership experience from Life Science, Pharma and Diagnostics in multinational pharmaceutical-chemical companies. During 11 years in executive management and board positions as CEO of the Czech Merck subsidiary and later Head of EEMEA region in Merck Millipore division, Karel built up a broad international network of top level managers in Biotech, Pharma and Life Science industries.

 

Joachim de Sterke

Joachim de Sterke

Board Member

Experienced executive with extensive experience across various disciplines and industries and has a proven track record of developing and growing a company from start up to a mid-size international company. Extensive finance, M&A, operations, analytics and business development experience in Deep Tech, SaaS and IaaS based environments driven by both direct- and indirect- sales. After he sequentially founded two venture backed international SaaS companies with US exits, Joachim de Sterke co-founded PhotonDelta, where he played a crucial role in expediting the development of the Dutch and EU integrated photonics markets. His impactful contributions include meticulously constructing a robust ecosystem and investment portfolio, and strategically cultivating individual partnerships and a global network to bolster the industry’s growth.

Today Joachim is Partner and Co-founder of PhotonVentures. PhotonVentures historically emerged from PhotonDelta as a deep-tech venture capital firm, purely focused on the key enabling technology of Integrated Photonics. Within PhotonVentures he holds multiple expert panel, board and advisory positions.